A005257 Stock Overview

Operates as a biotechnology company. More details

A005257 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	1/6

Risk Analysis

Dividend of 1.79% is not well covered by earnings or free cash flows

Earnings have declined by 59% per year over past 5 years

Debt is not well covered by operating cash flow

My Notes

Capture your thoughts, links and company narrative

Green Cross Holdings Corporation Competitors

Medy-Tox

KOSDAQ:A086900

₩834.7b

HLB TherapeuticsLtd

KOSDAQ:A115450

₩853.1b

Bioneer

KOSDAQ:A064550

₩491.2b

ABL Bio

KOSDAQ:A298380

₩1.3t

Price History & Performance

Summary of share price highs, lows and changes for Green Cross Holdings
Historical stock prices
Current Share Price	₩22,950.00
52 Week High	₩33,900.00
52 Week Low	₩20,950.00
Beta	0.84
1 Month Change	2.00%
3 Month Change	-9.11%
1 Year Change	-28.39%
3 Year Change	-55.52%
5 Year Change	27.50%
Change since IPO	1,464.48%

Recent updates

Shareholder Returns

	A005257	KR Biotechs	KR Market
7D	-2.3%	-3.9%	-3.7%
1Y	-28.4%	15.6%	-10.4%

Return vs Industry: A005257 underperformed the KR Biotechs industry which returned 15.6% over the past year.

Return vs Market: A005257 underperformed the KR Market which returned -10.4% over the past year.

Price Volatility

Is A005257's price volatile compared to industry and market?
A005257 volatility
A005257 Average Weekly Movement	8.2%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.7%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A005257 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A005257's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1967	151	Il-Sup Huh	www.gcbiopharma.com

Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille’s syndrome.

Green Cross Holdings Corporation Fundamentals Summary

How do Green Cross Holdings's earnings and revenue compare to its market cap?
A005257 fundamental statistics
Market cap	₩764.23b
Earnings (TTM)	-₩67.89b
Revenue (TTM)	₩2.18t

0.3x

P/S Ratio

-11.2x

P/E Ratio

Is A005257 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A005257 income statement (TTM)
Revenue	₩2.18t
Cost of Revenue	₩1.57t
Gross Profit	₩606.86b
Other Expenses	₩674.75b
Earnings	-₩67.89b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.50k
Gross Margin	27.82%
Net Profit Margin	-3.11%
Debt/Equity Ratio	82.5%

How did A005257 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

-20%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 16:07
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Green Cross Holdings Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sang-Hun Lee	iM Securities
Jae Hyun Kwon	Mirae Asset Securities Co., Ltd.
Ji-Won Shin	Mirae Asset Securities Co., Ltd. (Pre-Merger)

Green Cross Holdings KOSE:A005257 Stock Report